SCHEMBL556793

SCHEMBL556793

COCCNCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
DRD4 P21917 4/20 0.63
L3MBTL1 Q9Y468 1/20 0.61
MAOA P21397 1/20 0.57
CHRM2 P08172 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
DRD2 P14416 2/20 0.54
DRD3 P35462 2/20 0.54
SCN8A Q9UQD0 1/20 0.53
PPARG P37231 1/20 0.53
SIGMAR1 Q99720 2/20 0.52
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30321036 0.98 L3MBTL1 (0.64) MEN1KMT2ATDP1DRD4L3MBTL1
SCHEMBL21657638 0.89 DRD4 (0.56) MEN1KMT2ATDP1DRD4L3MBTL1
SCHEMBL7316643 0.88 MAOA (0.64) MEN1KMT2ATDP1DRD4MAOA
SCHEMBL8496914 0.86 LTA4H (0.59) MEN1KMT2ATDP1DRD4L3MBTL1
SCHEMBL7235032 0.82 GAA (0.65) MEN1KMT2ADRD4GAAMAPT
SCHEMBL12317 0.82 L3MBTL1 (0.64) MEN1KMT2ADRD4L3MBTL1CHRM2
SCHEMBL8252520 0.82 L3MBTL1 (0.64) MEN1KMT2ATDP1DRD4L3MBTL1
SCHEMBL893830 0.81 TDP1 (0.67) MEN1KMT2ATDP1DRD4MAOA
SCHEMBL11179375 0.81 TDP1 (0.67) MEN1KMT2ATDP1DRD4MAOA
SCHEMBL7574369 0.80 DRD4 (0.59) MEN1KMT2ATDP1DRD4MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME INFINEUM INTERNATIONAL LIMITED (GB) 2024-08-29 US claimed
EP-4410772-A2 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME Infineum International Limited (GB) 2024-08-07 EP claimed
CN-118440229-A Amine functional monomers and methods of making the same 英菲诺姆国际有限公司 2024-08-06 CN claimed
US-11261282-B2 PEO-PPO-PEO triblock bipolymers, with amphoteric endings, as demulsifying agents for heavy crude oils INSTITUTO MEXICANO DEL PETROLEO (MX) 2022-03-01 US claimed
US-20200347173-A1 PEO-PPO-PEO TRIBLOCK BIPOLYMERS, WITH AMPHOTERIC ENDINGS, AS DEMULSIFYING AGENTS FOR HEAVY CRUDE OILS INSTITUTO MEXICANO DEL PETROLEO (MX) 2020-11-05 US claimed
US-10125226-B2 Scale-up process of bifunctionalized triblock copolymers with secondary and tertiary amines, with application in dewatering and desalting of heavy crude oils INSTITUTO MEXICANO DEL PETROLEO (MX) 2018-11-13 US claimed
US-20140364566-A1 SCALE-UP PROCESS OF BIFUNCTIONALIZED TRIBLOCK COPOLYMERS WITH SECONDARY AND TERTIARY AMINES, WITH APPLICATION IN DEWATERING AND DESALTING OF HEAVY CRUDE OILS INSTITUTO MEXICANO DEL PETROLEO (MX) 2014-12-11 US claimed
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME INFINEUM INTERNATIONAL LIMITED (GB) 2024-08-29 US disclosed
EP-4410772-A2 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME Infineum International Limited (GB) 2024-08-07 EP disclosed
CN-118440229-A Amine functional monomers and methods of making the same 英菲诺姆国际有限公司 2024-08-06 CN disclosed
CN-116891462-A Mountain nuciferine derivative and preparation method and application thereof 上海如凌生物医药有限公司 2023-10-17 CN disclosed
US-11289238-B2 Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2022-03-29 US disclosed
US-20210174983-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC 2021-06-10 US disclosed
WO-1998025930-A2 USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 1998-06-18 WO disclosed
US-5352677-A Antihyperlipidemic agents KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-10-04 US disclosed
EP-0407200-B1 Cinnamamide derivatives KANEGAFUCHI CHEMICAL IND (JP) 1994-06-01 EP disclosed
US-5294624-A Antiartheriosclerosis KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-03-15 US disclosed
US-5294643-A Cinnamamide derivative KANEGAFUCHI KAGAKU KOGYO KABUSHIKI (JP) 1994-03-15 US disclosed
EP-0543861-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-06-02 EP disclosed
EP-0407200-A1 Cinnamamide derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME AMD1, HNMT, MAT1A MEN1 654/4885KMT2A 134/4885TDP1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.